Roche Holding AG
🇨🇭Switzerland
- Country
- 🇨🇭Switzerland
- Ownership
- Public
- Established
- 1896-01-15
- Employees
- 103.6K
- Market Cap
- $270.5B
- Website
- http://www.roche.com
Safety and Pharmacology Study of Atezolizumab Alone and in Combination With Bacille Calmette-Guérin (BCG) in High-Risk Non-Muscle-Invasive Bladder Cancer (NMIBC) Participants
Phase 1
Terminated
- Conditions
- Bladder Cancer
- Interventions
- Drug: AtezolizumabBiological: Bacille Calmette-Guérin
- First Posted Date
- 2016-06-07
- Last Posted Date
- 2021-10-28
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 24
- Registration Number
- NCT02792192
- Locations
- 🇺🇸
Duke University, Durham, North Carolina, United States
🇺🇸VA Portland Healthcare System, Portland, Oregon, United States
🇺🇸University of Chicago Medical Center, Chicago, Illinois, United States
Evaluation of [18F]RO6958948 as Tracer for Positron Emission Tomography (PET) Imaging of Tau Burden in Alzheimer's Disease Participants
Phase 1
Completed
- Conditions
- Alzheimer's Disease
- Interventions
- Drug: [18F]RO6958948
- First Posted Date
- 2016-06-07
- Last Posted Date
- 2017-11-01
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 4
- Registration Number
- NCT02792179
- Locations
- 🇺🇸
Johns Hopkins Medical Institutions, Johns Hopkins Outpatient Center, Baltimore, Maryland, United States
A Study of Peginterferon Alfa-2a in Participants With Chronic Hepatitis B Virus (HBV) in an Expanded Access Program
- First Posted Date
- 2016-06-06
- Last Posted Date
- 2017-02-06
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 24
- Registration Number
- NCT02791269
A Study of Peginterferon Alfa-2a Plus Ribavirin in Early Non-Responder Participants With Chronic Hepatitis C (CHC) Genotype 1, 4, 5, and 6
Phase 3
Terminated
- Conditions
- Hepatitis C, Chronic
- Interventions
- First Posted Date
- 2016-06-06
- Last Posted Date
- 2016-06-08
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 23
- Registration Number
- NCT02791256
A Study to Investigate Efficacy and Safety of Cobimetinib Plus Atezolizumab and Atezolizumab Monotherapy Versus Regorafenib in Participants With Metastatic Colorectal Adenocarcinoma (COTEZO IMblaze370)
Phase 3
Completed
- Conditions
- Colorectal Cancer
- Interventions
- First Posted Date
- 2016-06-02
- Last Posted Date
- 2019-12-11
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 363
- Registration Number
- NCT02788279
- Locations
- 🇺🇸
Yale Cancer Center; Medical Oncology, New Haven, Connecticut, United States
🇺🇸Florida Cancer Specialists; SCRI, Fort Myers, Florida, United States
🇺🇸Cancer Specialists; North Florida ;Jacksonville (AC Skinner Pkwy), Jacksonville, Florida, United States
Retrospective Analysis of Pulmonary Arterial Hypertension (PAH) and Related Complications in Juvenile Idiopathic Arthritis (JIA) Participants Treated With Biologic and Non-biologic Disease-modifying Anti-rheumatic Drugs (DMARDs)
Completed
- Conditions
- Juvenile Idiopathic Arthritis
- Interventions
- Drug: Non-Biologic DMARDsDrug: Biological DMARDs
- First Posted Date
- 2016-05-27
- Last Posted Date
- 2016-06-08
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 4557
- Registration Number
- NCT02784808
An Expanded Access Program of Pegfilgrastim (Neulastim) in Participants With Non-Hodgkin's Lymphoma (NHL)
Phase 4
Completed
- Conditions
- Non-Hodgkin's Lymphoma
- Interventions
- First Posted Date
- 2016-05-25
- Last Posted Date
- 2016-11-21
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 53
- Registration Number
- NCT02782845
A Pharmacokinetics, Pharmacodynamics and Safety Study of Warfarin in Combination With Tamiflu (Oseltamivir)
- First Posted Date
- 2016-05-23
- Last Posted Date
- 2016-10-26
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 20
- Registration Number
- NCT02780622
A Study of Erlotinib (Tarceva) in Participants With Non-Small Cell Lung Cancer (NSCLC)
- First Posted Date
- 2016-05-17
- Last Posted Date
- 2016-08-08
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 264
- Registration Number
- NCT02774278
A Study to Detect V-Raf Murine Sarcoma Viral Oncogene Homolog B1 (BRAF) V600 Mutation on Cell-Free Deoxyribonucleic Acid (cfDNA) From Plasma in Participants With Advanced Melanoma
- First Posted Date
- 2016-05-11
- Last Posted Date
- 2019-08-28
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 40
- Registration Number
- NCT02768207
- Locations
- 🇧🇪
UZ Brussel, Brussel, Belgium
🇧🇪UZ Antwerpen, Edegem, Belgium
🇧🇪Jessa Zkh (Campus Virga Jesse), Hasselt, Belgium
© Copyright 2025. All Rights Reserved by MedPath